Vertex’s New Products Dim as Analysts Eye Kidney Portfolio

By /

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid pain medicine Journavx and gene therapy Casgevy.

Scroll to Top